An exploration of women's knowledge and experience of perimenopause and menopause: An integrative literature review

O’Reilly, Kate; McDermid, Fiona; McInnes, Susan; Peters, Kathleen

doi:10.1111/jocn.16568

Cited by 14 publications

(24 citation statements)

References 53 publications

(200 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[31][32][33][34] However, these studies do not control or barely control for sex-specific health care needs, which have been reported to likely exist 32 and may be caused by increased health care needs during and years after fertility treatment and pregnancy, 35,36 health care related to the menstrual cycle, perimenopause or menopause, and contraception. [37][38][39][40][41][42][43][44][45][46][47][48] Interestingly, the difference in seeking health care between men and women is absent after the postmenopausal age of 65 years. 33 Apart from sex-specific health care needs, it has also become apparent that women historically have been receiving health care that has been designed for men, [49][50][51][52] is less effective for women, or may have adverse effects for women, 53 which could increase health care need.…”

Section: Biological Sex Differences Possibly Impacting the Abca4-ar D...mentioning

confidence: 99%

Representation of Women Among Individuals With Mild Variants in ABCA4-Associated Retinopathy

Cornelis,

IntHout,

Runhart

et al. 2024

JAMA Ophthalmol

View full text Add to dashboard Cite

ImportancePrevious studies indicated that female sex might be a modifier in Stargardt disease, which is an ABCA4-associated retinopathy.ObjectiveTo investigate whether women are overrepresented among individuals with ABCA4-associated retinopathy who are carrying at least 1 mild allele or carrying nonmild alleles.Data SourcesLiterature data, data from 2 European centers, and a new study. Data from a Radboudumc database and from the Rotterdam Eye Hospital were used for exploratory hypothesis testing.Study SelectionStudies investigating the sex ratio in individuals with ABCA4-AR and data from centers that collected ABCA4 variant and sex data. The literature search was performed on February 1, 2023; data from the centers were from before 2023.Data Extraction and SynthesisRandom-effects meta-analyses were conducted to test whether the proportions of women among individuals with ABCA4-associated retinopathy with mild and nonmild variants differed from 0.5, including subgroup analyses for mild alleles. Sensitivity analyses were performed excluding data with possibly incomplete variant identification. χ2 Tests were conducted to compare the proportions of women in adult-onset autosomal non–ABCA4-associated retinopathy and adult-onset ABCA4-associated retinopathy and to investigate if women with suspected ABCA4-associated retinopathy are more likely to obtain a genetic diagnosis. Data analyses were performed from March to October 2023.Main Outcomes and MeasuresProportion of women per ABCA4-associated retinopathy group. The exploratory testing included sex ratio comparisons for individuals with ABCA4-associated retinopathy vs those with other autosomal retinopathies and for individuals with ABCA4-associated retinopathy who underwent genetic testing vs those who did not.ResultsWomen were significantly overrepresented in the mild variant group (proportion, 0.59; 95% CI, 0.56-0.62; P &lt; .001) but not in the nonmild variant group (proportion, 0.50; 95% CI, 0.46-0.54; P = .89). Sensitivity analyses confirmed these results. Subgroup analyses on mild variants showed differences in the proportions of women. Furthermore, in the Radboudumc database, the proportion of adult women among individuals with ABCA4-associated retinopathy (652/1154 = 0.56) was 0.10 (95% CI, 0.05-0.15) higher than among individuals with other retinopathies (280/602 = 0.47).Conclusions and RelevanceThis meta-analysis supports the likelihood that sex is a modifier in developing ABCA4-associated retinopathy for individuals with a mild ABCA4 allele. This finding may be relevant for prognosis predictions and recurrence risks for individuals with ABCA4-associated retinopathy. Future studies should further investigate whether the overrepresentation of women is caused by differences in the disease mechanism, by differences in health care–seeking behavior, or by health care discrimination between women and men with ABCA4-AR.

show abstract

Section: Biological Sex Differences Possibly Impacting the Abca4-ar D...mentioning

confidence: 99%

Representation of Women Among Individuals With Mild Variants in ABCA4-Associated Retinopathy

Cornelis,

IntHout,

Runhart

et al. 2024

JAMA Ophthalmol

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] However, VMS has been a historically under-researched area with limited treatment options, despite affecting women's overall quality of life. [5][6][7] Recently, there has been increasing interest in understanding the mechanisms of hot flushing and the potential role of various treatments, such as selective serotonin reuptake inhibitors (SSRIs). The U.S. Food and Drug Administration approved a New Drug Application for Fezolinetant, which is an investigational, non-hormonal, oral compound for use in menopausal women undergoing moderate to severe VMS.…”

Section: Introductionmentioning

confidence: 99%

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Hassan¹,

Saleem²,

Samuel³

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them. Methods: PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were searched for relevant studies. The search was performed using the following keywords, which were customized to suit the specific databases/registers: menopause, women, neurokinin 3, and/or Fezolinetant. The search was conducted until December 20, 2022. This systematic review was conducted in compliance with the PRISMA Statement 2020 guidelines. Results: A total of 326 records were found, with 10 studies (enrolling 1993 women) selected for inclusion. The women received 40-mg doses of NK1/3 receptor antagonists twice daily, with follow-ups at 1 to 3 weeks. Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women. Conclusion: While the results should be interpreted with caution until further clinical trials validate the efficacy and safety of NK1/3 receptor antagonists among menopausal women, these findings suggest that they are promising targets for future pharmacological and clinical studies in addressing vasomotor symptoms.

show abstract

“…[2] Despite having a troublesome impact on the overall quality of life (QoL) of perimenopausal and postmenopausal women, vasomotor symptoms (VMS), which include hot flashes and night sweats, remain understudied, with only a few therapy options available. [3,4] The available treatments are not widely accessible (cognitive behavioral therapy [5] ), are limitedly efficacious (e.g., selective serotonin reuptake inhibitors [6] ), cause treatment-related adverse effects, are contraindicated (menopausal hormone therapy [MHT]) in women with personal or family history positive for breast cancer, [7] or are avoided in general due to long-term therapy risks, such as in case of estrogen-progesterone combined hormonal therapy (HT), [8] especially after Women's Health Initiative showed an increased risk of coronary heart disease and breast cancer. [9] A few randomized controlled trials (RCTs) were conducted recently to test the efficacy of neurokinin-3 (NK-3) antagonist, fezolinetant, for treating postmenopausal hot flashes in an effort to discover a novel, effective, and targeted nonhormonal medication for VMS.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis

Rahman,

Kashif,

Usman

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Menopause causes a variety of symptoms such as hot flashes and night sweats. While menopausal hormonal therapy has been used for managing postmenopausal vasomotor symptoms (VMS) for quite a while, it has a considerably poor safety profile. Objective: To review and analyze existing data to evaluate the efficacy of the neurokinin-3 antagonist, fezolinetant, in treating postmenopausal VMS and to assess its safety profile. Methods: A thorough literature search was performed on PubMed, Cochrane Library, and Google Scholar in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020, to find publications on the efficacy of fezolinetant for postmenopausal VMS. Changes in the frequency and severity scores of moderate/severe VMS and changes in the Hot Flash-Related Daily Interference Scale (HFRDIS), Greene Climacteric Scale (GCS), and Menopause-Specific Quality of Life (MENQoL) were the efficacy outcomes. Adverse events, drug-related treatment-emergent adverse effects (TEAEs), drug-related dropouts, hepatotoxicity, endometrial hyperplasia or tumor, and uterine bleeding were all safety outcomes. We used Review Manager 5.4 for pooling risk ratios (RRs) and mean differences (MDs) for dichotomous and continuous outcomes, respectively. A P value of < .05 was considered significant. Results: There was a significant reduction in mean daily VMS frequency at weeks 4 and 12 (MD, −2.36; 95% confidence interval [CI], −2.85 to −1.87; P < .00001, for week 12) and also a significant decrease in VMS severity scores in the treatment group. Furthermore, improvements in MENQoL, HFRDIS, and GCS scores were observed. There was no significant difference in adverse events while drug-related TEAEs (RR, 1.21; 95% CI, 0.90–1.63; P = .21) showed a slight increase with fezolinetant. Drug-related dropouts were again similar across the 2 groups. Uterine bleeding had a lower incidence while endometrial events and hepatotoxicity showed a statistically insignificant, increasing trend in the fezolinetant group. Discussion and implications: Fezolinetant can be a treatment option for postmenopausal VMS but warns of a risk increase in endometrial hyperplasia or tumors. The heterogeneity in the data being analyzed, short follow-up period, and small sample size in most of the included randomized controlled trials were the greatest limitations, which must be considered in further research and safety profile exploration.

show abstract

An exploration of women's knowledge and experience of perimenopause and menopause: An integrative literature review

Cited by 14 publications

References 53 publications

Representation of Women Among Individuals With Mild Variants in ABCA4-Associated Retinopathy

Representation of Women Among Individuals With Mild Variants in ABCA4-Associated Retinopathy

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis

Contact Info

Product

Resources

About